Natural history of HIV-control since seroconversion

Objectives:HIV-controllers spontaneously maintain HIV viremia at an undetectable level. We aimed to describe the delay to control from seroconversion, the duration of control, and risk factors for losing control. Methods:HIV-controllers were identified from a pooled dataset of 24 seroconverter cohorts from Europe, Australia, and Canada (CASCADE). HIV-controllers had at least five consecutive viral loads less than 400/500 copies/ml, while antiretroviral therapy naive, for at least 5 years after seroconversion. End of control was defined as two consecutive viral loads above 2000 copies/ml. Duration of control was described using Kaplan–Meier estimates; factors associated with duration of control were identified using a Cox model. CD4+ cell count evolution during control was described using a mixed model. Results:Of 9896 eligible seroconverters, we identified 140 (1.4%) HIV-controllers, the largest database of HIV-controllers followed from seroconversion. For 64 with viral load measured within 24 months from seroconversion, median delay to control was 16.7 (interquartile range: 7.8–37.9) months. Probability of maintaining control 20 years after seroconversion was 0.74 [95% confidence interval (CI): 0.64–0.85]. Occurrence of blips followed by return to undetectability did not increase the risk of loss of control [hazard ratio: 0.81 (95% CI: 0.10–6.70)]. However, CD4+ cell loss during control was significantly accelerated in individuals with blips. Conclusion:In most individuals, control occurred rapidly after seroconversion; however, more than 3 years were required to achieve control in 25% of HIV-controllers. Control may be sustained even when CD4+ cell levels are below 500 cells/&mgr;l, opening important new perspectives to understand the physiopathology underlying control.

[1]  C. Rouzioux,et al.  Hiv-1 Control after Transient Antiretroviral Treatment Initiated in Primary Infection: Role of Patient Characteristics and Effect of Therapy , 2012, Antiviral therapy.

[2]  A. Bergamaschi,et al.  Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. , 2011, Blood.

[3]  C. Rouzioux,et al.  CD4 Dynamics over a 15 Year-Period among HIV Controllers Enrolled in the ANRS French Observatory , 2011, PloS one.

[4]  E. Rosenberg,et al.  CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. , 2011, The Journal of clinical investigation.

[5]  E. Rosenberg,et al.  Impaired Replication Capacity of Acute/Early Viruses in Persons Who Become HIV Controllers , 2010, Journal of Virology.

[6]  B. Agan,et al.  Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. , 2009, The Journal of infectious diseases.

[7]  C. Rouzioux,et al.  Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  C. Rouzioux,et al.  Heterogeneity in HIV Suppression by CD8 T Cells from HIV Controllers: Association with Gag-Specific CD8 T Cell Responses1 , 2009, The Journal of Immunology.

[9]  D. Costagliola,et al.  Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV , 2009, AIDS.

[10]  H. Liao,et al.  Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers , 2009, AIDS.

[11]  C. Rouzioux,et al.  Early Control of HIV-1 Infection in Long-Term Nonprogressors Followed Since Diagnosis in the ANRS SEROCO/HEMOCO Cohort , 2009, Journal of acquired immune deficiency syndromes.

[12]  F. Brun-Vézinet,et al.  Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France , 2008, AIDS.

[13]  Terri Wrin,et al.  Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. , 2008, The Journal of infectious diseases.

[14]  O. Lambotte,et al.  HIV controllers: how do they tame the virus? , 2007, Trends in immunology.

[15]  H Putter,et al.  Tutorial in biostatistics: competing risks and multi‐state models , 2007, Statistics in medicine.

[16]  Asier Sáez-Cirión,et al.  HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype , 2007, Proceedings of the National Academy of Sciences.

[17]  Mario Roederer,et al.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.

[18]  Jeffrey N. Martin,et al.  Phenotypic, Functional, and Kinetic Parameters Associated with Apparent T-Cell Control of Human Immunodeficiency Virus Replication in Individuals with and without Antiretroviral Treatment , 2005, Journal of Virology.

[19]  C. Rouzioux,et al.  HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  C. Hallahan,et al.  HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors , 2002, Nature Immunology.

[21]  M. Prins,et al.  Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE , 2000, HIV medicine.

[22]  J. Margolick,et al.  Association of Race and Gender With HIV‐1 RNA Levels and Immunologic Progression , 2000, Journal of acquired immune deficiency syndromes.

[23]  F. Marincola,et al.  HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R H Lyles,et al.  Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. , 2000, The Journal of infectious diseases.

[25]  M. Rigsby,et al.  Comparison of the Amplicor HIV-1 monitor test and the nucleic acid sequence-based amplification assay for quantitation of human immunodeficiency virus RNA in plasma, serum, and plasma subjected to freeze-thaw cycles , 1997, Journal of clinical microbiology.